|
Donald Conklin joined the Alfacell Board of Directors in May 1997. Prior to his involvement with the Company, Mr. Conklin was a senior executive with Schering-Plough, a major worldwide Pharmaceutical firm. During his more than 35 years with Schering-Plough, he held a variety of key management positions within the firm. From 1986 to 1994, he served as President of Schering-Plough Pharmaceuticals. In this position, he was responsible for worldwide pharmaceutical operations, including the launch of INTRON Aź (interferon alfa-2b). Prior to this, Mr. Conklin had served as President of Schering USA and had held a variety of executive marketing positions in the United States, Europe, and Latin America. Immediately preceding his recent retirement, he was Chairman of Schering-Plough Health Care Products and an Executive Vice President of Schering-Plough Corporation. Mr. Conklin received his B.A. with highest honors from Williams College and his MBA degree from the Rutgers University School of Business. He currently serves on the Board of Directors of Vertex Pharmaceuticals, CytoTherapeutics, Biotranplant, and Ventiv Health.
| 